Rheumatic fever is an inflammatory disease mostly affecting children who are between 5 and 15 years old. It occurs when strep throat or scarlet fever isn't properly treated. Major cause of strep throat is infection with streptococcus bacteria.
Noticeable increase in number of patients suffering from acute rheumatic fever and increasing R&D activities by major players for development of advanced treatment are major factors expected to drive the growth of global rheumatic fever treatment market. There is rise in number of patient each year in hospitals suffering from various bacterial infections. Poor environment and lack of cleanliness in the middle-poor income countries is witnessing high patient pool for the disorder. Rheumatic fever mostly affects children and adolescents, especially where poverty is widespread and access to health services is limited. Government of developed and developing countries are spending high on R&D activities in order provide patients with advanced treatment. Their approach towards providing enhanced care through hospitals and advanced infrastructure is gaining traction. According to India Brand Equity Foundation, The Government of India approved continuation of ‘National Health Mission’ with a budget of US$ 5.10 Bn under the Union Budget 2021-22. The Government of India is planning to increase public health spending to 2.5% of the country's GDP by 2025.
Developing regulatory scenario related to healthcare sector and rising in investment by major players for development of new drugs are factors expected to segment the growth of global rheumatic fever treatment market. Government is focused on rising the awareness among consumers related to infections among children’s and make aware the consumers related to availability of treatment.
In 2019, the government of India is planning to procure penicillin centrally for three years and give it to all children between 5-15 years who have a sore throat. The drug will be dispensed through primary health centers or administered by ASHAs. This initiative is expected to aid government in dealing with the rising rheumatic fever concern.
In 2021, Teva Pharmaceuticals, a global drug manufacturing company launched 250 mg and 500 mg strength generic Erythromycin tablets. The launched product is a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin. This product launch is expected to help the company to enhance the business and increase the revenue share.
Manufacturer’s inclination towards enhancing the business in emerging economies due to availability of raw material and low cost labor coupled with focus on strategic acquisitions are factors expected to support the rheumatic fever treatment market growth. Factors such as high cost associated to drug development and lack of developed infrastructure in developing countries for R&D activities are expected to hamper the growth of global rheumatic fever treatment market. In addition, stringent government regulations related to product approval is expected to challenge the growth of target market. However, increasing government spending on healthcare sector and increasing public-private partnership for R&D activities are factors expected to create new opportunities for players operating in the rheumatic fever treatment market over the forecast period. In addition, government focus on strengthening the regional manufacturing capabilities is expected to create opportunities for manufacturers further supporting the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected account for major revenue share in the global rheumatic fever treatment market due to large number of geriatric population suffering from infections. In addition, availability of developed healthcare infrastructure for R&D activities, presence of large number of players operating in the country and introduction of new solutions are factors expected to augment the growth of regional market.
The global rheumatic fever treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Rheumatic Fever Treatment Market Segment Analysis, 2019
The global rheumatic fever treatment market is segmented into drug class, route of administration, and distribution channel. The dug class segment is bifurcated into antibiotics, disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsant medication, and others. Among distribution channel the online segment is expected to witness faster growth in the rheumatic fever treatment market. The players profiled in the report are Abbott, F. Hoffmann-La Roche Ltd, Novartis, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Bayer AG, and Bausch Health Companies Inc.
Market By Drug Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Market By Distribution Channel
Market By Route of Administration
Noticeable increase in number of patients suffering from acute rheumatic fever and increasing R&D activities by major players for development of advanced treatment are major factors expected to drive the growth of global rheumatic fever treatment market.
In drug class the antibiotics segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Abbott, F. Hoffmann-La Roche Ltd, Novartis, Bristol-Myers Squibb, and Eli Lilly and Company.
The North America is expected to account for major revenue share in the global market.
Factors such as high cost associated to drug development and lack of developed infrastructure in developing countries for R&D activities are expected to hamper the growth of global rheumatic fever treatment market.